Here are the 10-K annual reports from Aligos Therapeutics, Inc. (ALGS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ALGS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALGS filings page.
Aligos Therapeutics reported a 2025 net loss of $24.2 million, sharply improved from $131.2 million in 2024, mainly due to a non-cash $60.2 million gain from revaluing 2023 common warrants. Operating expenses remained high, with research and development at $69.5 million and general and administrative at $20.7 million.
Cash, cash equivalents and short-term investments totaled $77.8 million as of December 31, 2025, and the company used $82.5 million in operating cash during the year. Management expects existing funds to last only into the third quarter of 2026 and discloses substantial doubt about its ability to continue as a going concern without additional financing.
Aligos raised gross proceeds of $92.1 million in an October 2023 PIPE and approximately $105.0 million in a February 2025 private placement, while advancing its clinical-stage pipeline, including the Phase 2 B-SUPREME trial of HBV candidate pevifoscorvir sodium and Phase 2 work on MASH and coronavirus programs.